Otsuka buys PDL's IV Busulfex for $200mm
Executive Summary
In line with its planned asset sales and reorganization, PDL BioPharma (treatments for life-threatening diseases) has sold Otsuka Pharmaceutical Co. all rights to its IV Busulfex (busulfan) oncology product for $200mm cash.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Product Purchase
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice